ArticleMicrobial cell factories2026
Development of a novel hydroxylated recombinant human type III collagen TD-1-HrHC in Komagataella phaffii with transdermal and skin damage repair activity.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCollagen has been proven to have significant potential applications value in the fields of on medical aesthetics and cosmetics. However, due to its large molecular weight, collagen is difficult to effectively penetrate the skin barrier and reach the designated location to exert the expected activities. Transdermal peptide TD-1 is a short peptide consisting of only 11 amino acids, which can assist proteins such as insulin and cytokines to penetrate the skin barrier and reach the dermis layer. To maximize the transdermal and the efficacy of Collagen III in skincare, the shortest functional fragment that containing a triple helix structure of collagen protein fused with TD-1 were designed and evaluated for its transdermal activity, safety and efficacy.
resultsThe recombinant protein containing transdermal TD-1 fragment and a core active fragment of human collagen III (TD-1-HrHC) was co-expressed together with specific hydroxylase using the K. phaffii expression system, the products were purified by hydrophobic interaction chromatography (HIC) and ion-exchange chromatography (IEC). The TD-1-HrHC contains about 11.89% hydroxylation modifications that are similar to the natural human collagen III. The transdermal efficiency is 2077% measured by trans-well tests compare to the nature Collagen III isolated from animals. In addition, TD-1-HrHC able to promotes skin damage repairing through regulation series of barrier factors and differentiation factors in the HaCat cell model and promotes the repair of damaged skin and induces the generation of new-born collagen in mouse model. Moreover, it also shown an excellent ability to inhibit protein carbonylation on HaCat cells.
conclusionThis study demonstrates that TD-1-HrHC can effectively cross the skin barrier and has profound ability to inhibit protein carbonylation of skin and promote skin damage repairing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.